{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:34:57Z","timestamp":1787841297245,"version":"build-2784847793"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:00:00Z","timestamp":1558742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Waldenstr\u00f6m's macroglobulinemia (WM) is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients. Despite this, a significant proportion of patients require treatment because of hypersecretion of immunoglobulin M and the invasion of bone marrow and peripheral organs by neoplastic lymphoplasmacytic lymphoma cells. Historically, there has been a dearth of research and therapeutic advancements in the field of WM, with most understanding based on other, related B-cell lymphoid malignancies, including multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. Recently, there has been an increase in dedicated work to better explain the pathobiology of WM, which has identified several clinical and genetic markers that serve to prognosticate disease course and patient outcomes. Furthermore, this has led to dedicated clinical trials and the development of novel drugs\/regimens including the first Food and Drug Administration-approved agent for this diagnosis, ibrutinib. This review aims to document some of the recent advancements with respect to prognostic markers and therapeutic options for patients with WM, as well as certain selected novel treatments with unique mechanisms of action, that are currently under development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:37:38Z","timestamp":1559043458000},"page":"179-188","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Updates in prognostication and treatment of Waldenstr\u00f6m's macroglobulinemia"],"prefix":"10.4103","volume":"12","author":[{"given":"Pooja","family":"Advani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneel","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2019.05.002_b0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/CMAR.S94059","article-title":"New developments in the management of Waldenstrom macroglobulinemia","volume":"9","author":"Abeykoon","year":"2017","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.hemonc.2019.05.002_b0010","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3","article-title":"Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988\u20131994","volume":"82","author":"Groves","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2019.05.002_b0015","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2141.2007.06724.x","article-title":"Waldenstrom macroglobulinaemia","volume":"138","author":"Fonseca","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0020","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2005.03.144","article-title":"Diagnosis and management of Waldenstrom's macroglobulinemia","volume":"23","author":"Dimopoulos","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0025","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0030","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0035","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V82.10.3148.3148","article-title":"Incidence of Waldenstrom's macroglobulinemia","volume":"82","author":"Herrinton","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<229::AID-AJH11>3.0.CO;2-L","article-title":"Waldenstrom's macroglobulinemia in young African-American adults","volume":"60","author":"Ahmed","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3816\/CLM.2009.n.003","article-title":"Novel aspects pertaining to the relationship of Waldenstrom's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia","volume":"9","author":"McMaster","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.hemonc.2019.05.002_b0050","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Kyle","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0055","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1182\/blood-2009-10-247973","article-title":"Differential characteristics of Waldenstrom macroglobulinemia according to patterns of familial aggregation","volume":"115","author":"Royer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.leukres.2004.12.008","article-title":"Lymphoplasmacytic lymphoma\/Waldenstrom's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation","volume":"29","author":"Walsh","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.hemonc.2019.05.002_b0065","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3324\/haematol.2009.017251","article-title":"Pathophysiology of Waldenstrom's macroglobulinemia","volume":"95","author":"Stone","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2019.05.002_b0070","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/modpathol.2009.34","article-title":"Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia","volume":"22","author":"Morice","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0075","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13200","article-title":"CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P)-directed survival signalling in Waldenstrom macroglobulinaemia cells","volume":"168","author":"Cao","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0080","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood-2013-04-494849","article-title":"A new era for Waldenstrom macroglobulinemia: MYD88 L265P","volume":"121","author":"Treon","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0085","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2019.05.002_b0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.hemonc.2019.05.002_b0095","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia","volume":"122","author":"Yang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2000.18.1.214","article-title":"Waldenstrom's macroglobulinemia: clinical features, complications, and management","volume":"18","author":"Dimopoulos","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0105","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2141.2001.03144.x","article-title":"Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases","volume":"115","author":"Garcia-Sanz","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1172\/JCI116178","article-title":"Increased plasma viscosity as a reason for inappropriate erythropoietin formation","volume":"91","author":"Singh","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.hemonc.2019.05.002_b0115","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1038\/bcj.2015.28","article-title":"Waldenstrom macroglobulinemia: prognosis and management","volume":"5","author":"Oza","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hemonc.2019.05.002_b0120","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0125","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2015.124149","article-title":"Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy","volume":"100","author":"Kastritis","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2019.05.002_b0130","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1309\/4LCN-JMPG-5U71-UWQB","article-title":"Waldenstrom macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors","volume":"116","author":"Owen","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.V98.1.41","article-title":"Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)","volume":"98","author":"Dhodapkar","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0140","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2008-07-172080","article-title":"Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003","volume":"113","author":"Dhodapkar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06003.x","article-title":"Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia","volume":"133","author":"Ghobrial","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0150","first-page":"852","article-title":"Patients with the description of a new scoring system and its validation on 253 other patients","volume":"96","author":"Morel","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0155","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood.V83.10.2939.2939","article-title":"Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility","volume":"83","author":"Gobbi","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0160","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/cancers3010994","article-title":"Role of p53 in cell death and human cancers","volume":"3","author":"Ozaki","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hemonc.2019.05.002_b0165","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0170","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hemonc.2019.05.002_b0175","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2019.05.002_b0180","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 mutation and its prognostic significance in Waldenstrom's macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hemonc.2019.05.002_b0185","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0190","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2016-03-708263","article-title":"Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstrom macroglobulinemia","volume":"128","author":"Hunter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0195","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0200","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13897","article-title":"Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia","volume":"172","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0205","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1182\/blood-2014-03-564583","article-title":"C1013G\/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma","volume":"123","author":"Roccaro","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0210","first-page":"1074","article-title":"Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling","volume":"118","author":"Balabanian","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.hemonc.2019.05.002_b0215","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstrom's macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0220","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and management of Waldenstrom macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0225","unstructured":"NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas, 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx Accessed May 21, 2019."},{"key":"10.1016\/j.hemonc.2019.05.002_b0230","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","article-title":"Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0235","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(16)30166-1","article-title":"Once-weekly ofatumumab in untreated or relapsed Waldenstrom's macroglobulinaemia: an open-label, single-arm, phase 2 study","volume":"4","author":"Furman","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0240","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0245","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0250","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.hemonc.2019.05.002_b0255","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0260","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0265","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05\u2013180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0270","first-page":"3692","article-title":"Incidence of peripheral neuropathy in Waldenstrom macroglobulinemia patients at diagnosis","volume":"118","author":"Paba-Prada","year":"2011","journal-title":"ASH Annu Mtng Abstr"},{"key":"10.1016\/j.hemonc.2019.05.002_b0275","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-18-0152","article-title":"Prospective clinical trial of ixazomib, dexamethasone and rituximab as primary therapy in Waldenstrom macroglobulinemia","volume":"24","author":"Castillo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hemonc.2019.05.002_b0280","first-page":"1487","article-title":"Prospective Phase II study of ixazomib, dexamethasone and rituximab in previously untreated patients with Waldenstr\u00f6m macroglobulinemia","volume":"130","author":"Castillo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0285","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0290","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","article-title":"Maintenance Rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen","volume":"154","author":"Treon","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0295","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.15148","article-title":"Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstrom macroglobulinaemia","volume":"181","author":"Castillo","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0300","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3816\/CLML.2011.n.030","article-title":"Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia","volume":"11","author":"Treon","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hemonc.2019.05.002_b0305","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.3109\/10428194.2015.1012714","article-title":"Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia","volume":"56","author":"Tedeschi","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2019.05.002_b0310","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1179\/102453308X315915","article-title":"The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study","volume":"13","author":"Gilleece","year":"2008","journal-title":"Hematology"},{"key":"10.1016\/j.hemonc.2019.05.002_b0315","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","article-title":"High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0320","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbmt.2016.10.010","article-title":"Allogeneic transplantation for relapsed Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma","volume":"23","author":"Cornell","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2019.05.002_b0325","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2019.05.002_b0330","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1182\/blood-2008-04-150854","article-title":"Thalidomide and rituximab in Waldenstrom macroglobulinemia","volume":"112","author":"Treon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.05.002_b0335","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1078-0432.CCR-08-0862","article-title":"Lenalidomide and rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hemonc.2019.05.002_b0340","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.2009.24.0994","article-title":"Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0345","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1309\/AJCP15YFULCZHZVH","article-title":"Residual monotypic plasma cells in patients with Waldenstrom macroglobulinemia after therapy","volume":"135","author":"Barakat","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0350","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/sonc.2003.50074","article-title":"Immunophenotypic analysis of Waldenstrom's macroglobulinemia","volume":"30","author":"San Miguel","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0355","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2019.05.002_b0360","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1182\/blood.V124.21.4484.4484","article-title":"A systemic xenograft model of Waldenstr\u00f6m\u2019s macroglobulinemia demonstrates the potent anti-tumor effect of second generation CD19 directed chimeric antigen receptor modified T cells in this disease","volume":"124","author":"Smith","year":"2014","journal-title":"Blood"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S165838761930041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S165838761930041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2019.05.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:02Z","timestamp":1787838542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2019.05.002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2019.05.002","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}